Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|October 2, 2021
Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumorsAna Marcu, Andreas Schlosser, Anne Keupp, et al.
Cancer Research|January 30, 2019
Cognate Nonlytic Interactions between CD8<sup>+</sup> T Cells and Breast Cancer Cells Induce Cancer Stem Cell-like PropertiesRoland G Stein, Stefan Ebert, Laura Schlahsa, et al.
Blood Advances|November 9, 2022
Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic useDaniela Weber, Markus Weber, Elisabeth Meedt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 20, 2015
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumAndrew C Harris, Rachel Young, Steven Devine, et al.
Transplantation and Cellular Therapy|March 28, 2024
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHDMuna Qayed, Urvi Kapoor, Scott Gillespie, et al.
Transplantation and Cellular Therapy|September 2, 2021
Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host DiseaseMakda Getachew Zewde, George Morales, Isha Gandhi, et al.
Blood Immunology & Cellular Therapy|May 15, 2026
Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRMYu Akahoshi, Nikolaos Katsivelos, Ioannis E Louloudis, et al.
JCI Insight|February 15, 2017
An early-biomarker algorithm predicts lethal graft-versus-host disease and survivalMatthew J Hartwell, Umut Özbek, Ernst Holler, et al.
Blood Advances|April 20, 2022
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratificationAaron Etra, Stephanie Gergoudis, George Morales, et al.
Leukemia|February 6, 2020
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplantMina D Aziz, Jay Shah, Urvi Kapoor, et al.
Pageof 7